256 related articles for article (PubMed ID: 12718900)
1. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
2. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
[TBL] [Abstract][Full Text] [Related]
3. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
[TBL] [Abstract][Full Text] [Related]
4. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
5. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
6. Canavan disease: studies on the knockout mouse.
Matalon R; Michals-Matalon K; Surendran S; Tyring SK
Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
[TBL] [Abstract][Full Text] [Related]
7. rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System.
Ahmed SS; Schattgen SA; Frakes AE; Sikoglu EM; Su Q; Li J; Hampton TG; Denninger AR; Kirschner DA; Kaspar B; Matalon R; Gao G
Mol Ther; 2016 Jun; 24(6):1030-1041. PubMed ID: 27039844
[TBL] [Abstract][Full Text] [Related]
8. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
9. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
10. Redirecting
Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
[TBL] [Abstract][Full Text] [Related]
11. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
[TBL] [Abstract][Full Text] [Related]
12. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
13. A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.
Ahmed SS; Li H; Cao C; Sikoglu EM; Denninger AR; Su Q; Eaton S; Liso Navarro AA; Xie J; Szucs S; Zhang H; Moore C; Kirschner DA; Seyfried TN; Flotte TR; Matalon R; Gao G
Mol Ther; 2013 Dec; 21(12):2136-47. PubMed ID: 23817205
[TBL] [Abstract][Full Text] [Related]
14. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease.
Leone P; Janson CG; McPhee SJ; During MJ
Curr Opin Mol Ther; 1999 Aug; 1(4):487-92. PubMed ID: 11713764
[TBL] [Abstract][Full Text] [Related]
15. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
16. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
Becker I; Wang-Eckhardt L; Eckhardt M
J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
[TBL] [Abstract][Full Text] [Related]
17. Canavan disease: a monogenic trait with complex genomic interaction.
Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
[TBL] [Abstract][Full Text] [Related]
18. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease.
Leone P; Janson CG; Bilaniuk L; Wang Z; Sorgi F; Huang L; Matalon R; Kaul R; Zeng Z; Freese A; McPhee SW; Mee E; During MJ
Ann Neurol; 2000 Jul; 48(1):27-38. PubMed ID: 10894213
[TBL] [Abstract][Full Text] [Related]
19. Glial promoter selectivity following AAV-delivery to the immature brain.
von Jonquieres G; Mersmann N; Klugmann CB; Harasta AE; Lutz B; Teahan O; Housley GD; Fröhlich D; Krämer-Albers EM; Klugmann M
PLoS One; 2013; 8(6):e65646. PubMed ID: 23799030
[TBL] [Abstract][Full Text] [Related]
20. Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease.
Mersmann N; Tkachev D; Jelinek R; Röth PT; Möbius W; Ruhwedel T; Rühle S; Weber-Fahr W; Sartorius A; Klugmann M
PLoS One; 2011; 6(5):e20336. PubMed ID: 21625469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
